{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T03:39:30Z","timestamp":1784432370144,"version":"3.55.0"},"reference-count":27,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Recently, IgG autoantibodies against different paranodal proteins have been detected and this has led to important advances in the management of inflammatory neuropathies. In contrast, not much is known on IgM autoantibodies against paranodal proteins.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In the present study, we screened a large cohort of patients (n=140) with inflammatory neuropathies for IgM autoantibodies against neurofascin-155, neurofascin-186 or contactin-1.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>IgM autoantibodies against neurofascin-155 were detected by ELISA in five patients, four with inflammatory demyelinating polyradiculoneuropathy (CIDP) and one with Guillain-Barr\u00e9 syndrome (GBS), and were confirmed by ELISA-based preabsorption experiments and Western blot. Titres ranged from 1:100 to 1:400. We did not detect IgM anti-neurofascin-186 or anti-contactin-1 antibodies in this cohort. All patients presented with distally accentuated tetraparesis and hypesthesia. Remarkably, tremor was present in three of the patients with\u00a0CIDP and occurred in the patients with\u00a0GBS after the acute phase of disease. Nerve conduction studies revealed prolonged distal motor latencies and F wave latencies. Nerve biopsies showed signs of secondary axonal damage in three of the patients, demyelinating features in one patient. Teased fibre preparations did not demonstrate paranodal damage.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In summary, IgM neurofascin-155 autoantibodies may be worth testing in patients with inflammatory neuropathies. Their pathogenic role needs to be determined in future experiments.<\/jats:p><\/jats:sec>","DOI":"10.1136\/jnnp-2018-318170","type":"journal-article","created":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T16:20:11Z","timestamp":1530030011000},"page":"1145-1151","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":37,"title":["Neurofascin-155 IgM autoantibodies in patients with inflammatory neuropathies"],"prefix":"10.1136","volume":"89","author":[{"given":"Kathrin","family":"Doppler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Stengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luise","family":"Appeltshauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Grosskreutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy King","family":"Man Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Meinl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,6,26]]},"reference":[{"key":"2020050722283209000_89.11.1145.1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awv054"},{"key":"2020050722283209000_89.11.1145.2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000205"},{"key":"2020050722283209000_89.11.1145.3","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23794"},{"key":"2020050722283209000_89.11.1145.4","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31827689ad"},{"key":"2020050722283209000_89.11.1145.5","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-309916"},{"key":"2020050722283209000_89.11.1145.6","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww189"},{"key":"2020050722283209000_89.11.1145.7","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1212\/WNL.0000000000004773","article-title":"Neurofascin antibodies in autoimmune, genetic, and idiopathic neuropathies","volume":"90","author":"Burnor","year":"2018","journal-title":"Neurology"},{"key":"2020050722283209000_89.11.1145.8","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.expneurol.2016.10.006","article-title":"Complement deposition induced by binding of anti-contactin-1 auto-antibodies is modified by immunoglobulins","volume":"287","author":"Appeltshauser","year":"2017","journal-title":"Exp Neurol"},{"key":"2020050722283209000_89.11.1145.9","doi-asserted-by":"publisher","DOI":"10.1002\/ana.1088"},{"key":"2020050722283209000_89.11.1145.10","first-page":"356","article-title":". European Federation of Neurological Societies\/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-First Revision","volume":"15","author":"Van den Bergh","year":"2010","journal-title":"J Peripher Nerv Syst"},{"key":"2020050722283209000_89.11.1145.11","doi-asserted-by":"crossref","unstructured":"Doppler K , Appeltshauser L , Kr\u00e4mer HH , et al . Contactin-1 and neurofascin-155\/-186 are not targets of auto-antibodies in multifocal motor neuropathy. PLoS One 2015;10:e0134274.doi:10.1371\/journal.pone.0134274","DOI":"10.1371\/journal.pone.0134274"},{"key":"2020050722283209000_89.11.1145.12","doi-asserted-by":"crossref","unstructured":"Dyck PJ , Dyck PJB , Engelstad J . Pathological alterations of nerves. Peripheral Neuropathy. Philadelphia: Elsevier Saunders, 2005:733\u2013829.","DOI":"10.1016\/B978-0-7216-9491-7.50035-1"},{"key":"2020050722283209000_89.11.1145.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.03023.x"},{"key":"2020050722283209000_89.11.1145.14","doi-asserted-by":"publisher","DOI":"10.1111\/jns5.12023"},{"key":"2020050722283209000_89.11.1145.15","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70329-0"},{"key":"2020050722283209000_89.11.1145.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.06.003"},{"key":"2020050722283209000_89.11.1145.17","doi-asserted-by":"crossref","first-page":"290-293","DOI":"10.1016\/j.nmd.2016.10.008","article-title":"Paranodal lesions in chronic inflammatory demyelinating polyneuropathy associated with anti-Neurofascin 155 antibodies","volume":"27","author":"Vallat","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"2020050722283209000_89.11.1145.18","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1212\/WNL.0000000000002418","article-title":"Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy","volume":"86","author":"Devaux","year":"2016","journal-title":"Neurology"},{"key":"2020050722283209000_89.11.1145.19","doi-asserted-by":"crossref","unstructured":"Vlam L , Cats EA , Harschnitz O , et al . Complement activity is associated with disease severity in multifocal motor neuropathy. Neurol Neuroimmunol Neuroinflamm 2015;2:e119.doi:10.1212\/NXI.0000000000000119","DOI":"10.1212\/NXI.0000000000000119"},{"key":"2020050722283209000_89.11.1145.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2010.08.023"},{"key":"2020050722283209000_89.11.1145.21","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2010.205856"},{"key":"2020050722283209000_89.11.1145.22","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1093\/brain\/awx124","article-title":"Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy","volume":"140","author":"Delmont","year":"2017","journal-title":"Brain"},{"key":"2020050722283209000_89.11.1145.23","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-310097"},{"key":"2020050722283209000_89.11.1145.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2013.03.025"},{"key":"2020050722283209000_89.11.1145.25","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/acn3.248","article-title":"Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy","volume":"2","author":"Ogata","year":"2015","journal-title":"Ann Clin Transl Neurol"},{"key":"2020050722283209000_89.11.1145.26","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2016-314895"},{"key":"2020050722283209000_89.11.1145.27","doi-asserted-by":"crossref","unstructured":"Querol L , Rojas-Garc\u00eda R , Diaz-Manera J , et al . Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm 2015;2:e149.doi:10.1212\/NXI.0000000000000149","DOI":"10.1212\/NXI.0000000000000149"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2018-318170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T18:12:09Z","timestamp":1601057529000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2018-318170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,26]]},"references-count":27,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,10,10]]},"published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1136\/jnnp-2018-318170"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2018-318170","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,26]]}}}